All In Biotech

Drug Trial Radar · NCT07138898

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Last checked: Nov 20, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Dec 12, 2025

Primary completion

Jan 2028

Study completion Jan 2028

Sponsor

Lead sponsor
NYU Langone HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating room for rheumatology patients following shoulder replacements, comparing those who stop their immunosuppressants preoperatively for the same amount of time as suggested in the literature for hip and knee arthroplasty versus those who hold the medications for a shorter period of time preoperatively.

Conditions

  • Rheumatic Disease

Interventions

  • MethotrexateDrug

    Continue throughout perioperative period

  • SulfasalazineDrug

    Continue throughout perioperative period

  • HydroxychloroquineDrug

    Continue throughout perioperative period

  • LeflunomideDrug

    Continue throughout perioperative period

  • AzathioprineDrug

    Control group: Withhold the daily dose 1 week prior to surgery Intervention group: Withhold 2 days prior to surgery

  • MycophenolateDrug

    Control group: Withhold the daily dose 1 week prior to surgery Intervention group: Withhold 2 days prior to surgery

  • CyclosporineDrug

    Control group: Withhold the daily dose 1 week prior to surgery Intervention group: Withhold 2 days prior to surgery

  • TacrolimusDrug

    Control group: Withhold the daily dose 1 week prior to surgery Intervention group: Withhold 2 days prior to surgery

  • EtanerceptDrug

    Control group: Schedule surgery 2 weeks after last administered dose Intervention group: Schedule surgery 1 week after last administered dose

  • AdalimumabDrug

    Control group: Schedule surgery 3 weeks after last administered dose Intervention group: Schedule surgery 1 week after last administered dose

  • GolimumabDrug

    Control group: Schedule surgery 5 weeks after last administered 4-week subcutaneous dose or 9 weeks after last administered 8-week intravenous dose. Intervention group: Schedule surgery 2 weeks after last administered 4-week subcutaneous dose or 4 weeks after last administered 8-week intravenous dose.

  • CertolizumabDrug

    Control group: Schedule surgery 5 weeks after last administered dose. Intervention group: Schedule surgery 2 weeks after last administered dose.

  • InfliximabDrug

    Control group: Schedule surgery 9 weeks after last administered intravenous dose. Intervention group: Schedule surgery 4 weeks after last administered dose.

  • RituximabBiological

    Control: Schedule 7 months after last administered dose. Intervention group: Schedule 3 months after last administered dose.

  • BelimumabBiological

    Control group: Schedule surgery 2 weeks after last administered subcutaneous weekly dose or 5 weeks after last administered 4-week intravenous dose. Intervention group: Schedule surgery 1 week after last administered weekly dose or 2 weeks after last administered 4-week dose.

  • TocilizumabBiological

    Control group: Schedule surgery 2 weeks after last administered subcutaneous weekly dose or 5 weeks after last administered 4-week intravenous dose. Intervention group: Schedule surgery 1 week after last administered weekly dose or 2 weeks after last administered 4-week dose.

  • AnakinraBiological

    Control group: Schedule surgery 2 days after last administered daily dose. Experimental group: Schedule surgery 1 day after last administered daily dose.

  • CanakinumabBiological

    Control group: Schedule surgery 5 weeks after last administered 4-week dose. Intervention group: Schedule surgery 2 weeks after last administered 4-week dose.

  • AbataceptBiological

    Control group: Schedule surgery 2 weeks after last administered weekly subcutaneous dose or 5 weeks after last administered monthly intravenous dose. Intervention group: Schedule surgery 1 week after last administered weekly subcutaneous dose or 2 weeks after last administered monthly intravenous dose.

  • SecukinumabBiological

    Control group: Schedule surgery 5 weeks after last administered subcutaneous dose. Intervention group: Schedule surgery 2 weeks after last administered subcutaneous dose.

  • IxekizumabBiological

    Control group: Schedule surgery 5 weeks after last administered 4-week dose. Intervention group: Schedule surgery 2 weeks after last administered 4-week dose.

  • BimekizumabBiological

    Control group: Schedule surgery 9 weeks after last administered 8-week dose. Intervention group: Schedule surgery 4 weeks after last administered 8-week dose

  • UstekinumabBiological

    Control group: Schedule surgery 13 weeks after last administered 12-week dose. Intervention group: Schedule surgery 6 weeks after last administered 12-week dose.

  • GuselkumabBiological

    Control group: Schedule surgery 9 weeks after last administered 8-week dose. Intervention group: Schedule surgery 4.5 weeks after last administered 8-week dose.

  • RisankizumabBiological

    Control group: Schedule surgery 13 weeks after last administered 12-week dose. Intervention group: Schedule surgery 6-7 weeks after last administered 12-week dose.

  • TofacitinibDrug

    Control group: Schedule surgery 4 days after last administered daily dose. Intervention group: Schedule surgery 2 days after last administered daily dose.

  • UpadacitinibDrug

    Control group: Withhold 4 days prior to surgery Intervention group: Withhold 2 days prior to surgery

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of wound complicationsTime frame: 90-day post operation
  2. Incidence of superficial surgical site infectionsTime frame: 90-day post operation
  3. Incidence of deep surgical site infectionsTime frame: 90-day post operation
  4. Incidence of return trips to the operating roomTime frame: 90-day post operation
  5. Incidence of rheumatologic disease flaresTime frame: 90-day post operation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • NYU Langone Health

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.